Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

Overview

The main purpose of this study is to evaluate the efficacy and safety of Icotinib as neoadjuvant in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery.

Full Title of Study: “Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer: a Single Arm, Phase II Clinical Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 1, 2022

Detailed Description

Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy; then patients with clinical benefits receive surgical resection of the tumor. If there is curative effect of Icotinib according to the RECIST or pathological report, the patients will continue receive Icotinib for two years as adjuvant therapy after surgery or till progressive disease or unaccepted toxicity. The primary objective of this study is evaluate the efficacy and safety of Icotinib neoadjuvant therapy.

Interventions

  • Drug: Icotinib
    • Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.

Arms, Groups and Cohorts

  • Experimental: Icotinib
    • Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib as neoadjuvant therapy before surgery and adjuvant therapy or till progressive disease or unaccepted toxicity.

Clinical Trial Outcome Measures

Primary Measures

  • Objective Response Rate
    • Time Frame: eight weeks

Secondary Measures

  • R0 resection rate
    • Time Frame: eight weeks
  • Disease Control Rate
    • Time Frame: eight weeks
  • Decrease in cT-stage
    • Time Frame: eight weeks
  • pathologic complete remission rate
    • Time Frame: eight weeks
  • Time to Tumor Progression
    • Time Frame: five years after surgery
  • Overall survival
    • Time Frame: five years after surgery
  • Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
    • Time Frame: five years after surgery

Participating in This Clinical Trial

Inclusion Criteria

  • Histology or cytology confirmed Non-small Cell Lung Cancer; EGFR mutation (EGFR 19del and/or 21L858R) detected by tumor tissue biopsy of primary lesion or metastatic lesion or plasma ctDNA – No previous anti-tumor treatment such as surgery, chemotherapy, radiotherapy or biological therapy – Stage IIIA N2 NSCLC according to the pathological evidence of endobronchial ultrasound(EBUS) or PET-CT, the short-axis diameter of lymph node 1-2cm, and considered surgically resectable at baseline by the surgical oncologist – Sufficient tumor histological specimens (non-cytology) for molecular marker analysis – At least one lesion with measurable diameter and its longest diameter is large than 10 mm by CT measurement Exclusion Criteria:

  • Previous systemic anti-tumor treatment of Non-small Cell Lung Cancer, including cytotoxic drug therapy, targeted drug therapy (tyrosine kinase inhibitors or monoclonal antibodies) and experimental treatment, etc – Previous local radiotherapy of Non-small Cell Lung Cancer – Be allergic to any component of Icotinib tablet (Conmana) – Other cancers within five years prior to the treatment of this study. Except for cervical carcinoma, basal cell carcinoma and bladder epithelial neoplasm (including Ta and Tis) – Any instable systemic disease, including: active infection, high blood pressure out of control, unstable angina, onset of angina pectoris within the past 3 months, congestive heart failure, myocardial infarction, severe arrhythmia, liver, kidney or metabolic disease – Previous interstitial lung disease, drug-induced interstitial disease, radiation pneumonia requiring hormone therapy or any active intersexual lung disease with clinical evidence – Idiopathic pulmonary fibrosis detected by CT scan at baseline; – Not fully controlled eye inflammation or infections, or any condition that may lead to the above eye diseases – Human immunodeficiency virus infection – Patients undergoing major surgery or severe trauma within 2 months prior to the first use of the experimental drug – Patients with Small Cell Lung Cancer – Pregnant or lactating women – Neurological or psychiatric disorders history, including epilepsy or dementia – Other situations not appropriate to enter the group considering by the investigators

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Betta Pharmaceuticals Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shugeng Gao, Principal Investigator, Cancer Hospital, Chinese Academy of Medical Science
  • Overall Contact(s)
    • Shugeng Gao, MD, 13801185056, gaoshugeng@vip.sina.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.